Off-label use of omalizumab in non-asthma conditions: New opportunities

Expert Review of Respiratory Medicine

Volumn 3, Issue 3, 2009, Pages 299-308

  Morjaria, Jaymin B ^a   Polosa, Riccardo ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

ABPA; Allergic rhinitis; Anti IgE; Atopic dermatitis; Chronic urticaria; Latex allergy; Omalizumab; Peanut allergy; TNX 901

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO;

ABSENTEEISM; ADD ON THERAPY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ATOPIC DERMATITIS; BRONCHOPULMONARY ASPERGILLOMA; CHRONIC URTICARIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIC GASTROINTESTINAL DISORDER; HAY FEVER; HEALTH CARE COST; HUMAN; HYPERSENSITIVITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION SITE REACTION; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PEANUT ALLERGY; PERENNIAL RHINITIS; POLLEN ALLERGY; POSTMARKETING SURVEILLANCE; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEVERE PERSISTENT ASTHMA; TREATMENT DURATION; URTICARIA;

EID: 69949123296     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.11     Document Type: Review

References (92)

1. Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 402(6760 Suppl.), B18-B23 (1999).
2. Morjaria JB, Gnanakumaran G, Babu KS. Anti-IgE in allergic asthma and rhinitis: an update. Expert Opin Biol. Ther. 7(11), 1739-1747 (2007).
3. Parravicini V, Gadina M, Kovarova M et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat. Immunol. 3(8), 741-748 (2002).
4. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF et al. Structure and functions of CD23. Int. Rev. Immunol. 16(1-2), 113-128 (1997).
5. Van Cauwenberge PB. Nasal sensitization. Allergy 52(Suppl. 33), 7-9 (1997).
6. Poole JA, Meng J, Reff M, Spellman MC, Rosenwasser LJ. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 116(4), 780-788 (2005).
7. de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. J. Allergy Clin. Immunol. 103(5 Pt 2), S492-S496 (1999).
8. Gauchat JF, Lebman DA, Coffman RL, Gascan H, de Vries JE. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J. Exp. Med. 172(2), 463-473 (1990).
9. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108(2), 184-190 (2001).
10. Milgrom H, Berger W, Nayak A et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108(2), E36 (2001).
11. Milgrom H, Fick RB Jr, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. 341(26), 1966-1973 (1999).
12. Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18(2), 254-261 (2001).
13. Holgate ST, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 34(4), 632-638 (2004).
14. Buhl R, Soler M, Matz J et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur. Respir. J. 20(1), 73-78 (2002).
15. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy Asthma Immunol. 91(2), 154-159 (2003).
16. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60(3), 309-316 (2005).
17. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59(7), 701-708 (2004).
18. Bousquet J, Ayre G, Blogg M. Omalizumab added to best standard care reduces exacerbations in patients with severe persistent asthma according to GINA 2002 classification. Eur. Respir. J. 24(Suppl. 48) (220S), P1390 (2004).
19. Niven R, Chung, KF, Panahloo Z, Blogg M, Ayre G. Omalizumab in patients with inadequately controlled severe persitent allergic (IgE-mediated) asthma: a subgroup analysis of an open label trial. Am. J. Respir. Crit. Care Med. 175, A58 (2007).
20. Bousquet J, Cabrera P, Berkman N et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60(3), 302-308 (2005).
21. Chipps B, Corren J, Finn A, Hedgecock S, Fox H, Blogg M. Omalizumab significantly improves quality of life in patients with severe persistent asthma. J. Allergy Clin. Immunol. 115(2), S5-S19 (2005).
22. Finn A, Gross G, van Bavel J et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. 111(2), 278-284 (2003).
23. Bousquet J, van Cauwenbage P, Khaltaey N. Allergic rhinitis and its impact on asthma (ARIA) workshop report. J. Allergy Clin. Immunol. 108 (Suppl.), S147-S334 (2001).
24. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy 21(1), 77-83 (1991).
25. Adelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 106(2), 253-259 (2000).
26. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. cJ. Allergy Clin. Immunol. 98(4), 843-845 (1996).
27. Casale TB, Condemi J, LaForce C et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286(23), 2956-2967 (2001).
28. Nayak A, Casale T, Miller SD et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 24(5), 323-329 (2003).
29. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 55(4), 379-386 (2006).
30. Chervinsky P, Casale T, Townley R et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 91(2), 160-167 (2003).
31. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J. Allergy Clin. Immunol. 106(5 Suppl.), S201-S205 (2000).
32. Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J. Allergy Clin. Immunol. 103(1 Pt 1), 54-59 (1999).
33. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J. Allergy Clin. Immunol. 109(4), 636-642 (2002).
34. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J. Allergy Clin. Immunol. 109(1), 57-62 (2002).
35. Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59(7), 709-717 (2004).
36. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am. Rev. Respir. Dis. 147(4), 832-838 (1993).
37. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113(6), 1025-1034 (2004).
38. Casale TB. Status of immunotherapy: current and future. J. Allergy Clin. Immunol. 113(6), 1036-1039 (2004).
39. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341(7), 468-475 (1999).
40. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 99(4), 450-453 (1997).
41. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PATstudy). J. Allergy Clin. Immunol. 109(2), 251-256 (2002).
42. Van Cauwenberge P. ARIA: impact of compliance. Clin. Exp. Allergy Rev. 5, 3-6 (2005).
43. Norman PS. Immunotherapy: past and present. J. Allergy Clin. Immunol. 102(1), 1-10 (1998).
44. Greineder DK. Risk management in allergen immunotherapy. J. Allergy Clin. Immunol. 98(6 Pt 3), S330-S334 (1996).
45. Kuehr J, Brauburger J, Zielen S et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109(2), 274-280 (2002).
46. Rolinck-Werninghaus C, Hamelmann E, Keil T et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59(9), 973-979 (2004).
47. Kopp MV, Brauburger J, Riedinger F et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 110(5), 728-735 (2002).
48. Bez C, Schubert R, Kopp M et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin. Exp. Allergy 34(7), 1079-1085 (2004).
49. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. 87(1 Suppl. 1), 47-55 (2001).
50. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf. 23(4), 323-332 (2000).
51. Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J. Allergy Clin. Immunol. 110(6), 928-933 (2002).
52. Moverare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann. Allergy Asthma Immunol. 86(3), 337-342 (2001).
53. Casale TB, Busse WW, Kline JN et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 117(1), 134-140 (2006).
54. Klunker S, Saggar LR, Seyfert-Margolis V et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J. Allergy Clin. Immunol. 120(3), 688-695 (2007).
55. Sampson HA. Food allergy. Part 1: immunopathogenesis and clinical disorders. J. Allergy Clin. Immunol. 103(5 Pt 1), 717-728 (1999).
56. Sicherer SH, Munoz-Furlong A, Burks AW, Sampson HA. Prevalence of peanut and tree nut allergy in the US determined by a random digit dial telephone survey. J. Allergy Clin. Immunol. 103(4), 559-562 (1999).
57. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. J. Allergy Clin. Immunol. 107(2), 367-374 (2001).
58. Leung DY, Sampson HA, Yunginger JW et al. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 348(11), 986-993 (2003).
59. Chehade M. IgE and non-IgE-mediated food allergy: treatment in 2007. Curr. Opin. Allergy Clin. Immunol. 7(3), 264-268 (2007).
60. Agarwal S, Gawkrodger DJ. Latex allergy: a health care problem of epidemic proportions. Eur. J. Dermatol. 12(4), 311-315 (2002).
61. Sussman GL, Beezhold DH, Kurup VP. Allergens and natural rubber proteins. J. Allergy Clin. Immunol. 110(2 Suppl.), S33-S39 (2002).
62. Fish JE. Occupational asthma and rhinoconjunctivitis induced by natural rubber latex exposure. J. Allergy Clin. Immunol. 110(2 Suppl.), S75-S81 (2002).
63. Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J. Allergy Clin. Immunol. 106(3), 585-590 (2000).
64. Leynadier F, Doudou O, Gaouar H et al. Effect of omalizumab in health care workers with occupational latex allergy. J. Allergy Clin. Immunol. 113(2), 360-361 (2004).
65. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J. Am. Acad. Dermatol. 41(1), 72-77 (1999).
66. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J. Am. Acad. Dermatol. 44(1 Suppl.), S1-S12 (2001).
67. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J. Am. Acad. Dermatol. 54(1), 68-72 (2006).
68. Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FceRI. Cutis 80(1), 38-40 (2007).
69. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J. Am. Acad. Dermatol. 53(2), 338-340 (2005).
70. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 29(5), 530-537 (2008).
71. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Engl. J. Med. 328(22), 1599-1604 (1993).
72. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J. Allergy Clin. Immunol. 107(6), 1056-1062 (2001).
73. Niimi N, Francis DM, Kermani F et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J. Invest. Dermatol. 106(5), 1001-1006 (1996).
74. Kaplan AP. Chronic urticaria - new concepts regarding pathogenesis and treatment. Curr. Allergy Asthma Rep. 2(4), 263-264 (2002).
75. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann. Allergy Asthma Immunol. 99(2), 190-193 (2007).
76. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J. Allergy Clin. Immunol. 117(6), 1415-1418 (2006).
77. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J. Allergy Clin. Immunol. 122(3), 569-573 (2008).
78. de Almeida MB, Bussamra MH, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr. Respir. Rev. 7(1), 67-72 (2006).
79. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 60(8), 1004-1013 (2005).
80. Gibson PG. Allergic bronchopulmonary aspergillosis. Semin. Respir. Crit. Care Med. 27(2), 185-191 (2006).
81. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 116(3), 639-646 (1999).
82. Mastella G, Rainisio M, Harms HK et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur. Respir. J. 16(3), 464-471 (2000).
83. Stevens DA, Schwartz HJ, Lee JY et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N. Engl. J. Med. 342(11), 756-762 (2000).
84. Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 87(2), 245-246 (1991).
85. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr. Pulmonol. 43(6), 607-610 (2008).
86. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62(3), 276-277 (2007).
87. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr. Pulmonol. 43(12), 1249-1251 (2008).
88. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J. Allergy Clin. Immunol. 113(1), 11-28 (2004).
89. Spergel JM, Beausoleil JL, Mascarenhas M, Liacouras CA. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J. Allergy Clin. Immunol. 109(2), 363-368 (2002).
90. Foroughi S, Foster B, Kim N et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J. Allergy Clin. Immunol. 120(3), 594-601 (2007).
91. Xolair® (omalizumab) for subcutaneous use. Company leaflet. Genentech Inc., San Francisco, CA, USA.
92. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol. 120(6), 1373-1377 (2007).